Insights into the GALAD score: A new optimal cut-off for hepatocellular carcinoma
We strongly recommend incorporating this GALAD cut-off into clinical guidelines for the screening of patients with a compensated advanced CLD who are at high risk of developing HCC. Given the rapid global rise in metabolic-associated steatotic liver disease (MASLD)-related CLD, future research should prioritize larger MASLD cohorts to establish the most appropriate GALAD cut-off for diagnostic use, compared to healthy controls and to patients with other forms of CLD.
Authors
- Palma Aurelia Iacovazzi (ORCID: https://orcid.org/0000-0003-3590-4125)
- Patrizia Pontisso (ORCID: https://orcid.org/0000-0003-2077-9202)
- Gianluigi Giannelli (ORCID: https://orcid.org/0000-0002-5625-2499)
- Francesca Pavone
- Caterina Bonfiglio (ORCID: https://orcid.org/0000-0002-8650-348X)
- Andréa Martini (ORCID: https://orcid.org/0000-0002-7958-1906)
- Sergio Coletta (ORCID: https://orcid.org/0000-0003-3359-7010)
- Erica Villa (ORCID: https://orcid.org/0000-0001-6388-7022)
- Sherin Al Aoua
- Rosina Maria Critelli (ORCID: https://orcid.org/0000-0002-2313-2642)
- Raffaele Cozzolongo (ORCID: https://orcid.org/0000-0002-8343-5864)
- Nicola Carella (ORCID: https://orcid.org/0009-0001-5634-3251)
- Endrit Shahini (ORCID: https://orcid.org/0000-0002-4909-0436)
- Rossella Donghia (ORCID: https://orcid.org/0000-0002-9140-673X)
- Heike Bantel
- Anna Ancona
Institutions
- University of Modena and Reggio Emilia (IT)
- Medizinische Hochschule Hannover (DE)
- Azienda Ospedale - Università Padova (IT)
- Gastroenterology Hospital "Saverio de Bellis" (IT)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.3748/wjg.v31.i40.111727
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35